{"a":[{"_":"Why Legend Biotech stock fell 10% despite record Carvykti sales","$":{"href":"/pharma/why-legend-biotech-stock-fell-10-despite-record-carvykti-sales","hreflang":"en"}}]}

EarningsCarvyktiNegative

AI Analysis

Summary

Johnson & Johnson reported record Carvykti sales in multiple myeloma, but Legend Biotech stock fell 10% following comments made during J&J's earnings call. Despite strong revenue performance, market reaction was negative for the CAR-T therapy partner.

Financial Highlights

Revenue

record sales for Carvykti

Outcome Details

Record Carvykti sales reported; negative market reaction to LEGN stock despite strong revenue

Importance:5/10

Sentiment:

-0.30

earningsCAR-T therapypartnershipcommercial sales

Related Companies

$JNJ $LEGN

Read the original article

Published by FiercePharma on July 20, 2026 10:58 AM

Read Original